68
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Perspectives on the design and methodology of periconceptional nutrient supplementation trials

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Periconceptional supplementation could extend the period over which maternal and fetal nutrition is improved, but there are many challenges facing early-life intervention studies. Periconceptional trials differ from pregnancy supplementation trials, not only because of the very early or pre-gestational timing of nutrient exposure but also because they generate subsidiary information on participants who remain non-pregnant. The methodological challenges are more complex although, if well designed, they provide opportunities to evaluate concurrent hypotheses related to the health of non-pregnant women, especially nulliparous adolescents. This review examines the framework of published and ongoing randomised trial designs. Four cohorts typically arise from the periconceptional trial design — two of which are non-pregnant and two are pregnant — and this structure provides assessment options related to pre-pregnant, maternal, pregnancy and fetal outcomes. Conceptually the initial decision for single or micronutrient intervention is central — as is the choice of dosage and content — in order to establish a comparative framework across trials, improve standardisation, and facilitate interpretation of mechanistic hypotheses. Other trial features considered in the review include: measurement options for baseline and outcome assessments; adherence to long-term supplementation; sample size considerations in relation to duration of nutrient supplementation; cohort size for non-pregnant and pregnant cohorts as the latter is influenced by parity selection; integrating qualitative studies and data management issues. Emphasis is given to low resource settings where high infection rates and the possibility of nutrient-infection interactions may require appropriate safety monitoring. The focus is on pragmatic issues that may help investigators planning a periconceptional trial.

          Related collections

          Most cited references91

          • Record: found
          • Abstract: not found
          • Article: not found

          Statistics notes: Analysing controlled trials with baseline and follow up measurements.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Prevention of neural-tube defects with folic acid in China. China-U.S. Collaborative Project for Neural Tube Defect Prevention.

            Periconceptional administration of folic acid can reduce a woman's risk of having a fetus or infant with a neural-tube defect. As part of a public health campaign conducted from 1993 to 1995 in an area of China with high rates of neural-tube defects (the northern region) and one with low rates (the southern region), we evaluated the outcomes of pregnancy in women who were asked to take a pill containing 400 microg of folic acid alone daily from the time of their premarital examination until the end of their first trimester of pregnancy. Among the fetuses or infants of 130,142 women who took folic acid at any time before or during pregnancy and 117,689 women who had not taken folic acid, we identified 102 and 173, respectively, with neural-tube defects. Among the fetuses or infants of women who registered before their last menstrual period and who did not take any folic acid, the rates of neural-tube defects were 4.8 per 1000 pregnancies of at least 20 weeks' gestation in the northern region and 1.0 per 1000 in the southern region. Among the fetuses or infants of the women with periconceptional use of folic acid, the rates were 1.0 per 1000 in the northern region and 0.6 per 1000 in the southern region. The greatest reduction in risk occurred among the fetuses or infants of a subgroup of women in the northern region with periconceptional use who took folic acid pills more than 80 percent of the time (reduction in risk, 85 percent as compared with the fetuses or infants of women who registered before their last menstrual period and who took no folic acid; 95 percent confidence interval, 62 to 94 percent) [corrected]. In the southern region the reduction in risk among the fetuses or infants of women with periconceptional use of folic acid was also significant (reduction in risk, 41 percent; 95 percent confidence interval, 3 to 64 percent). Periconceptional intake of 400 microg of folic acid daily can reduce the risk of neural-tube defects in areas with high rates of these defects and in areas with low rates.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group.

              A randomised double-blind prevention trial with a factorial design was conducted at 33 centres in seven countries to determine whether supplementation with folic acid (one of the vitamins in the B group) or a mixture of seven other vitamins (A,D,B1,B2,B6,C and nicotinamide) around the time of conception can prevent neural tube defects (anencephaly, spina bifida, encephalocele). A total of 1817 women at high risk of having a pregnancy with a neural tube defect, because of a previous affected pregnancy, were allocated at random to one of four groups--namely, folic acid, other vitamins, both, or neither. 1195 had a completed pregnancy in which the fetus or infant was known to have or not have a neural tube defect; 27 of these had a known neural tube defect, 6 in the folic acid groups and 21 in the two other groups, a 72% protective effect (relative risk 0.28, 95% confidence interval 0.12-0.71). The other vitamins showed no significant protective effect (relative risk 0.80, 95% Cl 0.32-1.72). There was no demonstrable harm from the folic acid supplementation, though the ability of the study to detect rare or slight adverse effects was limited. Folic acid supplementation starting before pregnancy can now be firmly recommended for all women who have had an affected pregnancy, and public health measures should be taken to ensure that the diet of all women who may bear children contains an adequate amount of folic acid.
                Bookmark

                Author and article information

                Contributors
                b.j.brabin@liverpool.ac.uk
                s.gies@itg.be
                sowens@3mac.com
                yclaeys@itg.be
                udalessandro@mrc.gm
                tintohalidou@yahoo.fr
                loretta.Brabin@manchester.ac.uk
                Journal
                Trials
                Trials
                Trials
                BioMed Central (London )
                1745-6215
                30 January 2016
                30 January 2016
                2016
                : 17
                : 58
                Affiliations
                [ ]Clinical Division, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L35QA UK
                [ ]Global Child Health Group, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
                [ ]Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
                [ ]Northumbria Healthcare NHS Foundation Trust, North Shields, NE29 8NH UK
                [ ]Clinical Sciences Department, Institute of Tropical Medicine, Antwerp, Belgium
                [ ]Medical Research Council Unit (MRC), Fajara, The Gambia
                [ ]London School of Hygiene and Tropical Medicine, London, UK
                [ ]Institute of Tropical Medicine, Antwerp, Belgium
                [ ]Clinical Research Unit of Nanoro (URCN/IRSS), Nanoro, Burkina Faso
                [ ]Institute of Cancer Sciences, University of Manchester, Manchester, UK
                Article
                1124
                10.1186/s13063-015-1124-0
                4736099
                26833080
                2502372d-46d4-4f94-954c-b120b128bb9c
                © Brabin et al. 2016

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 20 March 2015
                : 15 December 2015
                Categories
                Review
                Custom metadata
                © The Author(s) 2016

                Medicine
                periconceptional,pregnancy,placenta,iron,folic acid,micronutrients,adherence
                Medicine
                periconceptional, pregnancy, placenta, iron, folic acid, micronutrients, adherence

                Comments

                Comment on this article